Screening of human antibody fab fragment against HBsAg and the construction of its dsFv form

International Journal of Biological Sciences

Volumn 4, Issue 2, 2008, Pages 103-110

  Jia, Leili ^a   Yu, Jiyun ^b   Song, Hongbin ^a,c   Liu, Xuelin ^a   Ma, Weina ^a   Xu, Yuanyong ^a   Zhang, Chuanfu ^a   Dong, Shicun ^a   Li, Qiao ^a,b,c  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chain shuffling; dsFv; Fab; HBsAg; Phage antibody; Point mutagenesis

Indexed keywords

DISULFIDE STABILIZED FV FRAGMENT; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV;

ANTIBODY AFFINITY; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE MUTATION; HEAVY CHAIN; LIGHT CHAIN; MOLECULAR CLONING; MUTAGENESIS; PERIPHERAL LYMPHOCYTE; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; CHEMISTRY; GENE EXPRESSION REGULATION; GENE LIBRARY; HUMAN; METABOLISM; SITE DIRECTED MUTAGENESIS;

HEPATITIS B VIRUS;

GENE EXPRESSION REGULATION; GENE LIBRARY; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 44849084812     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4.103     Document Type: Article

References (31)

1. Sidhu SS, Koide S. Phage display for engineering and analyzing protein interaction interfaces. Curr Opin Struct Biol. 2007;17:481-7.
2. Brekke O.H., Loset G.A.. New technologies in therapeutic antibody development. Curr. Opin. Pharmacol. 2003; 3: 544-50.
3. Thullier P, Lafaye P, Megret F, et al. A recombinant Fab neutralizes dengue virus in vitro. J Biotechnol. 1999; 69: 183-90.
4. Skerra A. Bacterial expression of immunoglobulin fragments. Curr Opin Immunol. 1993; 5: 256-62.
5. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science. 1988; 240: 1038-41.
6. Glockshuber R., Malia M., Pfitzinger I.,et al. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 1990; 29: 1362-7.
7. Kirsch M, Zaman M, Meier D, et al. Parameters affecting the display of antibodies on phage. J Immunol Meth. 2005;301:173-85.
8. Marks JD, Hoogenboom HR, Griffiths AD, et al. Molecular evolution of proteins on filamentous phage. J Biol Chem. 1992;267:16007-10.
9. Bird RE, Walker BW. Single chain variable regions. Trends Biotech. 1991; 9:132-7.
10. Webber K. O., Reiter Y., Brinkmann U., et al. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol. 1995; 32: 249-58.
11. Eisenbach C, Sauer P, Mehrabi A, et al. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant. 2006;20:111-6.
12. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11: 97-107.
13. Lu SC, Yan LN, Li B, et al. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. Hepatobiliary Pancreat Dis Int. 2004;3:26-32.
14. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudineresistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349-60.
15. Ning D, Junjian X, Qing Z, et al. Production of recombinant humanized anti- HBsAg Fab fragment from Pichia pastoris by frmentation. J Biochem Mol Biol. 2005;38:294-9.
16. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol. 1995; 17: 261-81.
17. Rosenblum JS and Barbas CF. Synthetic antibodies in antibody engineering, 2nd ed. New York: Oxford University Press. 1995:89-116
18. Barbas CF, Lerner RA. Combinatorial immunoglobin libraries on the surface of phage (phAb): rapid selection of antigen-specific Fabs. Comp Methods Enzymol. 1991; 2:119.
19. Begum N., Horiuchi S., Tanaka Y., et al. New approach for generation of neutralizing antibody against human T-cell leukaemia virus type-I (HTLV-I) using phage clones. Vaccine. 2002; 20:1281-9.
20. Song HB, Mao CS, Chen W, et al. Construction and DNA sequencing of dsFv mutated gene of human antibody to HBsAg. J Cell Mol Immunol. 1998; 14:241-3.
21. Bachlder R, Bilancieri J, Lin WY et al. A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4. J Virol. 1995; 69:5734-42.
22. Ohlin M, Owman H, Mach M, et al. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol. 1996; 33:47-56.
23. Buchner J, Rudolph R. Renaturation, purification and characterization of recombinant Fab-fragment produced in Escherichia coli. Biotechnology. 1991; 9: 157-62.
24. Kabat EA, Wu TT, Perry HM, et al. Sequences of proteins of immunological interest, 5th ed. US: NIH publication. 1991: 91.
25. Barik S, Galinski M. "Mega-primer" method of PCR: Increased template concentration improves yield. BioTechniques. 1991; 10:489-95.
26. Bio-Rad Laboratories. Methods in electroporation: Bacterial- transformation and pulse controller instrument manual. Herculs, CA: Bio-Rad Laboratories. 1989.
27. Changshou Gao, Shenlan Mao, Gunnar Kaufmann et al. A method for the generation of combinatorial antibody libraries using pIX phage display. PNAS. 2002; 99: 12612-6.
28. Zebedee SL, et al. Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Nati Acad Sci USA. 1992; 89:3175-9.
29. Kang AS, Burten DR, Lerner RA. Combinatorial immunoglobulin libraries in phage λ. Methods Enzymol. 1991; 2:111-8.
30. Reiter Y, Briter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nature Biotechnol. 1996; 14:1239-45.
31. Reiter Y, Pastan I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res. 1996; 2:245-52.